Oncology - FOI Response Register

FoI Number
2025-272
Subject
Oncology
Date Received
17/07/2025
Request and Response
  1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

•     Atezolizumab (Tecentriq)

•     Durvalumab (Imfinzi)

•     Nivolumab (Opdivo)

•     Pembrolizumab (Keytruda)

•     Chemotherapy

•     Radiotherapy

•     Chemotherapy AND Radiotherapy

•     Osimertinib

Zero

  1. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?  

Nil

  1. How many patients has your Trust treated in total in the past 3 months for

•     Stage 2 Non-Small Cell Lung Cancer

•     Stage 3 Non-Small Cell Lung Cancer

Nil

  1. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

•     Atezolizumab

•     Pembrolizumab monotherapy

•     Pembrolizumab with chemotherapy

•     Nivolumab

•     Osimertinib                         

•     Durvalumab

•     Chemotherapy

•     Radiotherapy

•     Chemotherapy and Radiotherapy

Nil

  1. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with:

•     Chemotherapy

•     Radiotherapy                                   

•     Chemotherapy + Radiotherapy

Nil

  1. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

•           Durvalumab  

Nil